Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05693766 · ClinicalTrials.gov registry record · Phase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
A Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma, sponsored by Sonya Reid.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 3
- Study locations
NCT05693766: Recruiting Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma, sponsored by Sonya Reid.
NCT05693766 is a Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma that is actively recruiting participants, run by Sonya Reid. The registered enrollment target is 64 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05693766, a Phase 2 study of Metastatic Breast Cancer and Invasive Mammary Carcinoma, is actively recruiting participants, sponsored by Sonya Reid.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Conditions Studied
Interventions
- DRUG Capecitabine
- OTHER Endocrine-therapy
- OTHER MammoPrint ® and BluePrint assays
Study Locations (3)
Alabama
- University of Alabama Birmingham - Birmingham
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2037-08-31 |
| Phase | Phase 2 |
What NCT05693766 shows while recruiting
NCT05693766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT05693766 reports a single indexed study location in Alabama, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT05693766 about?
NCT05693766 is a clinical study titled "Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort". This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
What is the current status of trial NCT05693766?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-28. Estimated completion is 2037-08-31.
What conditions does trial NCT05693766 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Invasive Mammary Carcinoma.
What interventions are being tested in trial NCT05693766?
The interventions under investigation include: Capecitabine (DRUG), Endocrine-therapy (OTHER), MammoPrint ® and BluePrint assays (OTHER).
Who is sponsoring clinical trial NCT05693766?
This trial is sponsored by Sonya Reid, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05693766 being conducted?
This trial has 3 study locations across Alabama, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05693766's enrollment target sits among peer trials
64 76th of 139 higher than 64 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI